newsfilter
← Earnings
Earnings Releases·

Lyell Immunopharma — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $45.5 million for Q3 2026, widening from $38.8 million in the prior-year period, while revenue declined to $3,000 from $15,000; R&D expenses rose to $40.9 million driven by increased clinical activity.
  • Announced an $80.0 million private placement in November 2026, which combined with the $194.0 million cash balance as of September 30, 2026, is expected to fund operations through 2028.
  • PiNACLE pivotal trial enrollment is on track to complete by year-end 2026, with data disclosure expected mid-2027 and a BLA submission targeted for the second half of 2027.
  • Updated clinical data for ronde-cel showed a 91% overall response rate and 77% complete response rate in the 3L+ PiNACLE trial, with no Grade ≥ 3 CRS observed and manufacturing capacity exceeding 3,000 doses annually.
Company
LYELL IMMUNOPHARMA INC
Sector
Healthcare
Industry
Biotechnology